What is the t(14;18) Translocation in Follicular Lymphoma?
At a Glance
The t(14;18) translocation is an acquired genetic mutation found in about 85% of follicular lymphoma patients. It swaps pieces of chromosomes 14 and 18, causing the overproduction of the BCL2 protein. This prevents natural cell death, causing B-cells to build up in lymph nodes.
In this answer
3 sections
If you are looking at your pathology report and wondering what “t(14;18)” means, you are looking at the foundational genetic hallmark of follicular lymphoma. The t(14;18) translocation is a specific genetic mutation found in approximately 85% of people diagnosed with this condition [1][2]. It is not a mutation you inherited from your parents, but rather an acquired change in your B-cells (a type of white blood cell) that acts as the initial spark in the disease [1].
If your report does not show this mutation, do not panic. About 15% of follicular lymphomas develop through other genetic pathways, and the absence of t(14;18) does not mean your diagnosis is wrong or necessarily indicate a worse prognosis.
The “Genetic Swap”: What is a Translocation?
Inside every cell in your body, your DNA is packaged into structures called chromosomes. Humans typically have 23 pairs of chromosomes. A translocation happens when two chromosomes break and swap pieces with each other.
In the case of t(14;18), the “t” stands for translocation, and the numbers “14” and “18” tell us exactly where the swap occurred [2]. A piece of chromosome 14 trades places with a piece of chromosome 18. This might sound like a simple mix-up, but it brings two specific genes together that were never meant to be neighbors.
The BCL2 Protein: Switching Off Natural Cell Death
To understand why this swap causes follicular lymphoma, we have to look at the two genes that get forced together:
- The IGH Gene (Chromosome 14): In B-cells, the immunoglobulin heavy chain (IGH) gene is naturally highly active because it tells the cell to make antibodies to fight infections [1]. It is essentially stuck in the “on” position.
- The BCL2 Gene (Chromosome 18): This gene produces the BCL2 protein, which acts as an anti-death signal [1]. Normally, when cells become old, damaged, or are no longer needed, they undergo a natural, programmed cell suicide called apoptosis. BCL2 stops this process.
When the t(14;18) translocation occurs, the BCL2 gene is moved right next to the highly active IGH gene [1]. Because the IGH gene is always turned “on,” it forces the BCL2 gene to stay “on” as well [1].
This causes the cell to overproduce the BCL2 protein, which effectively blocks the cell’s natural ability to die [1]. Instead of living their normal lifespan and dying off to make room for new cells, these B-cells become somewhat “immortal” and slowly pile up in your lymph nodes [1]. This cellular pile-up is directly responsible for the swollen glands you may have noticed when you were first diagnosed.
Why Other Mutations Matter
While the t(14;18) translocation is the engine that drives the overproduction of BCL2, it is usually not enough on its own to cause follicular lymphoma to fully develop [3][4]. In fact, this specific translocation can sometimes be found in tiny amounts in healthy individuals without ever causing cancer [3].
For the disease to progress, the B-cells typically need to accumulate secondary genetic mutations [5][6]. These “second hits” often involve genes that control how the cell matures and interacts with your immune system, such as KMT2D, EZH2, or TNFRSF14 [7][8].
Pathologists primarily use the t(14;18) translocation to confirm your diagnosis, but secondary mutations are what increasingly guide specific treatment choices [1][9]. For example, mutations in the EZH2 gene occur in about 25% of follicular lymphoma patients and are now a direct target for certain newer therapies [8][10]. Understanding your complete genetic profile helps your doctors predict how your lymphoma might behave and choose the most effective treatments for you [9][7]. To get this complete profile, your care team may need to run an advanced test called Next-Generation Sequencing (NGS) on your biopsy sample, which you can ask them about during your next visit.
Common questions in this guide
What does the t(14;18) translocation mean on my pathology report?
Is the t(14;18) mutation inherited from my parents?
What if my follicular lymphoma doesn't have the t(14;18) mutation?
Why are secondary mutations like EZH2 important in follicular lymphoma?
Related questions
Show more
Get notified when new evidence is published on Follicular lymphoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (10)
- 1
CREBBP gene mutations are frequently detected in in situ follicular neoplasia.
Schmidt J, Ramis-Zaldivar JE, Bonzheim I, et al.
Blood 2018; (132(25)):2687-2690 doi:10.1182/blood-2018-03-837039.
PMID: 30401710 - 2
Head and neck follicular lymphoma with marginal zone differentiation and BCL2 translocation t(14;18) in both nodular and extranodular sites: a case report with mini-review.
Vageli DP, Doukas PG, Batrakouli O, et al.
Oral surgery, oral medicine, oral pathology and oral radiology 2023; (136(4)):e139-e148 doi:10.1016/j.oooo.2023.05.005.
PMID: 37516620 - 3
Precursory or early lesions of follicular lymphoma: clinical features, pathology, and genetics.
Oishi N
Journal of clinical and experimental hematopathology : JCEH 2023; (63(2)):65-72 doi:10.3960/jslrt.23010.
PMID: 37380471 - 4
Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype.
Vogelsberg A, Steinhilber J, Mankel B, et al.
Haematologica 2021; (106(10)):2673-2681 doi:10.3324/haematol.2020.254854.
PMID: 32855278 - 5
Prevalence of BCL-2/J(H) Translocation in Healthy African Americans.
Colon-Otero G, Van Wier SA, Ahmann GJ, et al.
Annals of hematology 2017; (96(1)):51-55 doi:10.1007/s00277-016-2842-4.
PMID: 27730341 - 6
Transformation of t(14;18)-negative follicular lymphoma to plasmablastic lymphoma: a case report with analysis of genetic evolution.
Lim S, Koh J, Bae JM, et al.
Diagnostic pathology 2024; (19(1)):86 doi:10.1186/s13000-024-01512-2.
PMID: 38909266 - 7
Generation and External Validation of a Histologic Transformation Risk Model for Patients with Follicular Lymphoma.
Fernández-Miranda I, Pedrosa L, González-Rincón J, et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2024; (37(7)):100516 doi:10.1016/j.modpat.2024.100516.
PMID: 38763418 - 8
Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma.
Nagy Á, Bátai B, Kiss L, et al.
Journal of internal medicine 2023; (294(3)):295-313 doi:10.1111/joim.13674.
PMID: 37259686 - 9
Bridging clinicopathologic features and genetics in follicular lymphoma: Towards enhanced diagnostic accuracy and subtype differentiation.
Bosch-Schips J, Parisi X, Climent F, Vega F
Human pathology 2025; (156()):105676 doi:10.1016/j.humpath.2024.105676.
PMID: 39490765 - 10
Performance of the cobas EZH2 mutation test on clinical samples from non-Hodgkin lymphoma patients.
Shyu JY, Schlag PA, Karwowska SM, et al.
PloS one 2023; (18(12)):e0292251 doi:10.1371/journal.pone.0292251.
PMID: 38096164
This page explains follicular lymphoma pathology terminology for educational purposes only. Always discuss your specific genetic test results and treatment plan with your oncologist or hematologist.